Journal ArticleOPEN ACCESS

Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis

  • McInnes I
  • Anderson J
  • Magrey M
  • et al.
New England Journal of Medicine (2021) 384(13) 1227-1239
DOI: 10.1056/nejmoa2022516
252Citations
Citations of this article
208Readers
Mendeley users who have this article in their library.

Abstract

Abstract Background The Janus kinase inhibitor upadacitinib is a potential treatment for psoriatic arthritis. The efficacy and safety of upadacitinib as compared with adalimumab, a tumor necrosis f...

Cite

CITATION STYLE

APA

McInnes, I. B., Anderson, J. K., Magrey, M., Merola, J. F., Liu, Y., Kishimoto, M., … Behrens, F. (2021). Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis. New England Journal of Medicine, 384(13), 1227–1239. https://doi.org/10.1056/nejmoa2022516

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free